Artifact Reduction
Real-time selective reduction of eye, muscle and electrode artifacts
Company profile
Company profile
Persyst Development operates at the intersection of neuroscience and computer science as the worldwide leader in EEG (electroencephalography) software. The company provides comprehensive Computer Assisted Review of EEG (C.A.R.E) solutions that enable accurate, efficient, and rapid review of EEG data for both high-volume institutions and community clinics. Their flagship product, Persyst 15, offers the most advanced seizure detection capabilities available, with clinical validation showing non-inferiority to human expert reviewers. The platform includes sophisticated spike detection, comprehensive EEG trending tools, real-time artifact reduction, and multi-patient monitoring capabilities. Persyst is uniquely positioned as the only EEG trending and detection software integrated, sold, and supported by every major EEG manufacturer including Micromed, Natus, Nihon Kohden, Cadwell, and Compumedics. The company has pioneered mobile EEG monitoring with Persyst Mobile, the first FDA-cleared EEG monitoring and review application for mobile devices. Persyst serves neurologists, epileptologists, and healthcare institutions worldwide, with their technology recognized as the standard of care at leading epilepsy centers. The company maintains a strong commitment to research and scientific validation, publishing findings in peer-reviewed journals and collaborating with clinical partners to advance the field of quantitative EEG for neurodiagnostics.
Company description Persyst Development official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Embedded · Hybrid · On Premise deployment with recorded integration context.
Recorded integration context: Cadwell, Compumedics, Micromed, Natus, Nihon Kohden.
Company milestones
Launch of Persyst 15 described as 'Our Biggest Version Ever', FDA clearance of Persyst Mobile as first mobile EEG monitoring application, 2025 ANA-Persyst Professional Development Award announced at 150th Annual Meeting of American Neurological Association
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Real-time selective reduction of eye, muscle and electrode artifacts
Comprehensive patient monitoring from wherever you are
Monitor multiple patients simultaneously with Persyst technology
EEG Review and Analysis Software for Computer Assisted Review of EEG (C.A.R.E)
EEG Electrical Source Imaging for advanced neurological analysis
First FDA-cleared EEG monitoring and review application for mobile devices
Cloud-based EEG access and collaboration platform
Most advanced seizure detector available with non-inferior performance to human experts
Spike detection shown to be non-inferior to skilled human reviewers
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · Jun 1, 2025
DICOM encoding of annotation and montage data for waveform recordings.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · Jun 1, 2025
Quantitative Electroencephalography (EEG) Predicting Acute Neurologic Deterioration in the Pediatric Intensive Care Unit: A Case Series.Journal of child neurology · Jan 1, 2022
Seizure Detection: Interreader Agreement and Detection Algorithm Assessments Using a Large Dataset.Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society · Sep 1, 2021
Pearls & Oy-sters: Cyclic Seizures and Heart Rate Variability.Neurology · Mar 23, 2021
Reply to "What it should mean for an algorithm to pass a statistical Turing test for detection of epileptiform discharges".Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · Jul 1, 2017
Clinical validation
No linked records are currently available.
Regulatory
K182181 · 510k · Nov 29, 2018
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Seizure detection algorithm performance validated in peer-reviewed study
Spike detection accuracy
EEG data analysis and monitoring
EEG monitoring and analysis as standard of care
Used by top epilepsy centers as ranked by US News and NAEC
05 · Leadership
Leadership profiles and professional links from the current Company record.
Michael Jaramillo
Unknown
06 · Company updates
Recent articles published on Persyst Development's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.